TY - JOUR
T1 - Pancreatic acinar cell carcinoma
T2 - A comprehensive review
AU - Calimano-Ramirez, Luis Fernando
AU - Daoud, Taher
AU - Gopireddy, Dheeraj Reddy
AU - Morani, Ajaykumar C.
AU - Waters, Rebecca
AU - Gumus, Kazim
AU - Klekers, Albert Russell
AU - Bhosale, Priya R.
AU - Virarkar, Mayur K.
N1 - Funding Information:
We thank Kelly Kage for the beautiful illustrations.
Publisher Copyright:
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
PY - 2022/10/28
Y1 - 2022/10/28
N2 - Acinar cell carcinoma (ACC) is a rare pancreatic malignancy with distinctive clinical, molecular, and morphological features. The long-term survival of ACC patients is substantially superior to that of pancreatic adenocarcinoma patients. As there are no significant patient series about ACCs, our understanding of this illness is mainly based on case reports and limited patient series. Surgical resection is the treatment of choice for patients with the disease restricted to one organ; however, with recent breakthroughs in precision medicine, medicines targeting the one-of-a-kind molecular profile of ACC are on the horizon. There are no standard treatment protocols available for people in which a total surgical resection to cure the condition is not possible. As a result of shared genetic alterations, ACCs are chemosensitive to agents with activity against pancreatic adenocarcinomas and colorectal carcinomas. The role of neoadjuvant or adjuvant chemoradiotherapy has not been established. This article aims to do a comprehensive literature study and present the most recent information on acinar cell cancer.
AB - Acinar cell carcinoma (ACC) is a rare pancreatic malignancy with distinctive clinical, molecular, and morphological features. The long-term survival of ACC patients is substantially superior to that of pancreatic adenocarcinoma patients. As there are no significant patient series about ACCs, our understanding of this illness is mainly based on case reports and limited patient series. Surgical resection is the treatment of choice for patients with the disease restricted to one organ; however, with recent breakthroughs in precision medicine, medicines targeting the one-of-a-kind molecular profile of ACC are on the horizon. There are no standard treatment protocols available for people in which a total surgical resection to cure the condition is not possible. As a result of shared genetic alterations, ACCs are chemosensitive to agents with activity against pancreatic adenocarcinomas and colorectal carcinomas. The role of neoadjuvant or adjuvant chemoradiotherapy has not been established. This article aims to do a comprehensive literature study and present the most recent information on acinar cell cancer.
KW - Acinar cell carcinoma
KW - Chemotherapy
KW - Imaging
KW - Immunohistochemical stains
KW - Molecular features
KW - Pancreas
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85141461662&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141461662&partnerID=8YFLogxK
U2 - 10.3748/wjg.v28.i40.5827
DO - 10.3748/wjg.v28.i40.5827
M3 - Review article
C2 - 36353206
AN - SCOPUS:85141461662
SN - 1007-9327
VL - 28
SP - 5827
EP - 5844
JO - World journal of gastroenterology
JF - World journal of gastroenterology
IS - 40
ER -